{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:58:11Z","timestamp":1792699091195,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.beem.2023.101826","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T16:49:28Z","timestamp":1696092568000},"page":"101826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Burosumab: Current status and future prospects"],"prefix":"10.1016","volume":"38","author":[{"given":"Alpesh","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"ADHR Consortium","year":"2000","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.beem.2023.101826_bib2","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/JME-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J Mol Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2023.101826_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.beem.2023.101826_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/2230-8210.93733","article-title":"Hypophosphatemic rickets","volume":"16","author":"Jagtap","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101826_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.beem.2023.101826_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.3544","article-title":"Burosumab: at long last, an effective treatment for FGF23-associated hypophosphatemia","volume":"33","author":"Collins","year":"2018","journal-title":"J Bone Min Res"},{"issue":"8","key":"10.1016\/j.beem.2023.101826_bib7","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10189","key":"10.1016\/j.beem.2023.101826_bib8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11914-021-00669-9","article-title":"Burosumab for pediatric X-linked hypophosphatemia","volume":"19","author":"Imel","year":"2021","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"10.1016\/j.beem.2023.101826_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.beem.2023.101826_bib11","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2023.101826_bib12","unstructured":"\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761068s000lbl.pdf\u3009. [Accessed June 11, 2023]."},{"key":"10.1016\/j.beem.2023.101826_bib13","unstructured":"\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761068s005lbl.pdf\u3009. [Accessed June 11, 2023]."},{"key":"10.1016\/j.beem.2023.101826_bib14","unstructured":"\u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/crysvita#authorisation-details-section\u3009. [Accessed June 11, 2023]."},{"issue":"11","key":"10.1016\/j.beem.2023.101826_bib15","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Min Res"},{"issue":"4","key":"10.1016\/j.beem.2023.101826_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Min Res"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"issue":"5","key":"10.1016\/j.beem.2023.101826_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the radiographic global impression of change scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Min Res"},{"issue":"1","key":"10.1016\/j.beem.2023.101826_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-020-00705-3","article-title":"New therapies for hypophosphatemia-related to FGF23 excess","volume":"108","author":"Athonvarangkul","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"21","key":"10.1016\/j.beem.2023.101826_bib20","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of Burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2023.101826_bib23","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of Burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101826_bib24","first-page":"dgad230","article-title":"Burosumab versus phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a sub-group analysis by dose level","author":"Imel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101826_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient-reported outcomes from a randomized, active-controlled, open-label, Phase 3 Trial of Burosumab versus conventional therapy in children with X-linked hypophosphatemia","volume":"108","author":"Padidela","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"10.1016\/j.beem.2023.101826_bib26","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2023.101826_bib27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, Phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Min Res"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of Burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.beem.2023.101826_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.beem.2023.101826_bib30","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a Phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Min Res"},{"issue":"1","key":"10.1016\/j.beem.2023.101826_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-022-06516-6","article-title":"Long-term use of burosumab for the treatment of tumor-induced osteomalacia","volume":"34","author":"Crotti","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2023.101826_bib32","first-page":"22","article-title":"Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment","volume":"2023","author":"Aliberti","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"10.1016\/j.beem.2023.101826_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Min Res"},{"issue":"2","key":"10.1016\/j.beem.2023.101826_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a Phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Min Res"},{"issue":"12","key":"10.1016\/j.beem.2023.101826_bib35","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/jbmr.4318","article-title":"Burosumab for tumor-induced osteomalacia: not enough of a good thing","volume":"36","author":"Hartley","year":"2021","journal-title":"J Bone Min Res"},{"issue":"10","key":"10.1016\/j.beem.2023.101826_bib36","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgac433","article-title":"Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)","volume":"107","author":"Bai","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101826_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.beem.2023.101826_bib38","article-title":"A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets","volume":"17","author":"Huynh","year":"2022","journal-title":"Bone Rep"},{"issue":"11","key":"10.1016\/j.beem.2023.101826_bib39","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR"},{"issue":"10189","key":"10.1016\/j.beem.2023.101826_bib40","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(19)31054-2","article-title":"Burosumab treatment of children with X-linked hypophosphataemic rickets","volume":"393","author":"Gordon","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.beem.2023.101826_bib41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1210\/clinem\/dgac488","article-title":"Approach to Hypophosphatemic Rickets","volume":"108","author":"Ackah","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23001008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23001008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:25Z","timestamp":1761498025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1521690X23001008"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101826","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burosumab: Current status and future prospects","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101826"}}